Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Amgen launches an AbbVie Humira biosimilar in the U.S.

Published 01/31/2023, 01:56 PM
Updated 01/31/2023, 02:02 PM
© Reuters Amgen launches an AbbVie Humira biosimilar in the US

© Reuters Amgen launches an AbbVie Humira biosimilar in the US

By Sam Boughedda

After a dip earlier in the session, AbbVie (NYSE:ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ:AMGN) announcing AMJEVITA, a biosimilar to Humira, is now available in the United States.

AMJEVITA was the first biosimilar to AbbVie's Humira approved by the U.S. Food and Drug Administration and is now available in the U.S. at a list price 5% below the current Humira list price, Amgen said.

"With today's announcement, AMJEVITA is the first U.S. biosimilar to Humira®, a medicine used by more than a million patients living with certain serious inflammatory diseases," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. "With our track record of developing and manufacturing biologics and decades of experience in inflammation, Amgen is uniquely equipped to supply this biosimilar medicine while reducing costs."

Reacting to the news, Truist analysts told investors in a note that "AMGN (Hold) is offering both a 55% discount, as well as 5% discount for their Humira biosimilar Amjevita on current Humira list price (typically ~30% expected), which in our view creates an interesting pricing dynamic."

"We note AMGN will be first-to-market with their biosimilar 40mg Humira (called Amjevita) at WAC price of 55% discount to Humira's current list price, which we believe payers will care about pricing and volume supply dynamics. We also note Amjevita is also available at list price 5% below current Humira list price," wrote the analysts.

They added: "While Humira is a Part D drug, the biggest questions are 1) how much price erosion AMGN will have to do to keep Enbrel and Otezla on formulary; 2) How much will Abbvie (ABBV, Buy) cut Humira; 3) Will payors be forced to switch or keep Humira on par as 95% of Humira users are long-term."

The analysts went on to state that while several companies have been approved or have approvals pending for their biosimilar Humira, they believe Amgen and Pfizer (NYSE:PFE) will probably own the largest market shares, with Coherus BioSciences Inc (NASDAQ:CHRS) "potentially grabbing a piece of the pie later."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.